Beyond survival: reassessing long-term immunologic risks of thymectomy

To the Editor, We read with interest the recent study by Resio et al[1], which – drawing on SEER and NCDB data – suggests that total thymectomy for localized thymoma does not elevate 5-year mortality or secondary cancer risk, implying long-term safety. However, equating survival with immune safety overlooks the thymus’s persistent role in adult immune regulation – especially as long-term survivorship increasingly depends on immune resilience. Here, we outline conceptual and methodological limitations that may obscure the long-term immunologic consequences of thymectomy and their implications for risk stratification and surgical decision-making. This study complies with the TITAN 2025 guidelines for transparent and ethical reporting of AI-assisted research[2]. First, 5-year survival is a crude proxy for immune integrity. The thymus maintains naïve T cell output, T Cell Receptor (TCR) diversity, and central tolerance into adulthood. While short-term mortality may remain unchanged, thymectomy can induce subclinical immune deficits – manifesting as attenuated vaccine responses, viral reactivation, or late-onset autoimmunity[3]. Such outcomes lie beyond the resolution of Surveillance, Epidemiology, and End Results Program (SEER) or National Cancer Database (NCDB). Without intermediate endpoints – such as infection rates, autoimmunity incidence, or T cell profiling – the study lacks biological granularity. In an era of immunotherapy and pathogen sensitivity, reducing thymic function to a survival statistic risks missing long-latency consequences. Second, survival parity may be confounded by physiologic mismatch in comparator groups. Patients with resected breast Ductal Carcinoma In Situ (DCIS) or thyroid cancer – predominantly female – benefit from estrogen-mediated T cell resilience, potentially masking immune deficits linked to thymectomy[4]. Moreover, these surgeries preserve immune architecture and elicit minimal systemic inflammation, unlike thymectomy, which disrupts central immune compartments. Compounding this, the study lacks age stratification. Adults under 40 retain active thymopoiesis and may be more vulnerable to long-term immunologic compromise. Pooling across age groups likely dilutes age-specific effects, risking false-negative conclusions. Without immunologically analogous controls and age-sensitive analyses, survival comparisons may obscure biologically meaningful vulnerabilities. Third, distinguishing “total” from “partial” thymectomy based on SEER and NCDB codes presumes procedural coding reliably reflects operative reality – an assumption increasingly fragile amid minimally invasive and robotic approaches. Without operative or histologic confirmation, the resection extent becomes a probabilistic proxy. Moreover, patients undergoing partial resection may differ systematically by age, comorbidity, or anatomy, introducing indication bias that undermines causal inference[5]. The study’s restriction to <5 cm localized thymomas also excludes advanced cases where immuno-oncologic trade-offs are most pronounced, limiting generalizability to real-world scenarios where tumor control must be weighed against immune preservation[6]. In summary, while the study offers short-term reassurance, equating 5-year survival with thymectomy safety may obscure the thymus’s enduring role in adult immune regulation. The absence of immunologic endpoints, age-stratified risk modeling, and procedural granularity limits our understanding of long-term consequences – particularly for younger adults with active thymopoiesis. As thymectomy increasingly intersects with immunotherapy eligibility, infection risk, and survivorship care, a more biologically anchored evaluative framework is warranted. Until such data emerge, definitive safety claims remain premature. Future studies should incorporate immune-based metrics – such as naïve T cell recovery, vaccine responsiveness, and infection susceptibility – to clarify the long-term immunologic cost of thymic compromise. This correspondence underscores the need for outcome-driven, biologically grounded, and immunologically informed risk assessment frameworks in surgical oncology.